THE 21TH CONGRESS ON INNOVATION IN REPRODUCTIVE MEDICINE
Improving our skills through education

Frankfurt, Germany | May 14-16, 2015

www.cogi.org | cogi@comtecmed.com

HONORARY CHAIRMAN
Diethelm Wallwiener, Germany

CONGRESS CHAIRPERSONS
Klaus Diedrich, Germany
Andreas Schmutzler, Germany
Zeev Shoham, Israel

ORGANIZING COMMITTEE
Christian De Geyter, Switzerland
Klaus Diedrich, Germany
Norbert Gleicher, USA
Ludwig Kiesel, Germany
Andreas Schmutzler, Germany
Zeev Shoham, Israel
Thomas Strowitzki, Germany
Seang Lin Tan, Canada
Gurkan Ucuncu, Turkey
Ariel Weissman, Israel

PRELIMINARY SCIENTIFIC PROGRAM

THURSDAY, MAY 14, 2015

14:30-16:00
SESSION 1: TIME-LAPSE TECHNOLOGY WHAT IS THE GOAL AND WHAT ARE THE DIFFERENCES BETWEEN THE TECHNOLOGIES?
Laboratory aspects: Simon Fishel, UK
Clinical aspects: Milton Leong, HK
Dark field technology: Jon Aizpurua, Spain
Pitfalls related to the technology: Norbert Gleicher, USA

16:00-16:30 Coffee Break

16:30-18:00 SESSION 2: DEBATE: NEW RECOMBINANT FSH ON THE MARKET: VIEWS FROM THE EXPERTS
Molecular aspects and background: Hermann Allgaier, Germany
Clinical perspective: Klaus Diedrich, Germany
Supporting the current available recombinant FSH: Klaus Bühler, Germany

18:00-19:00 SESSION 3: ARE WE REACHING THE TIME WHEN SCIENCE MEETS WISHFUL THINKING?
Autologous mitochondrial injection to increase energy in oocytes: Robert Casper, Canada
Non-invasive prenatal diagnosis from the blood of pregnant women- finally available in clinical practice: Wolfgang Holzgreve, Germany
FRIDAY, MAY 15, 2015

HALL A

08:30-10:30 | SESSION 4A: NEW INNOVATION IN CRYOBIOLOGY

Debate: Social freezing of oocytes and ovarian tissue to maintain fertility and postpone menopause: low cost, easy administration and good outcome. Is it such? For: Claus Yding Andersen, Denmark Against: Michael von Wolff, Switzerland

Pregnancies and live births after 20 transplantations of cryopreserved ovarian tissue: The technology is now available for all: Ralf Ditrich, Germany

Oocyte cryopreservation for fertility preservation in cancer patients – how good is it? If you have one go and perhaps a reduced response due to sickness, what should be the stimulation protocol? Kenny Rodríguez-Wallberg, Sweden

10:30-11:00 | Coffee Break

11:00-12:30 | SESSION 5A: GETTING THE BEST PREGNANCY RATE: STIMULATION AND ET

IVF outcomes in patients with extremely poor prognosis: Ariel Weissman, Israel

Superovulation protocol for poor responders: a new approach: Basil Tatlatzis, Greece

Treating infertile premature ovarian insufficiency (POI) patients: ovarian fragmentation followed by Akt stimulation treatment in vitro and autotransplantation (in vitro activation – IVA): Kazuhiko Kawamura, Japan

GnRH agonist triggering oocyte maturation for all ART cycles: Four years’ experience and results: Robert Fischer, Germany

12:30-13:30 | Lunch Break

13:30-15:30 | SESSION 6A: GETTING THE BEST PREGNANCY RATE: STIMULATION AND ET (2)

Debate: Neoadjuvants in stimulation protocols: what can we add For: Gurkan Uncu, Turkey Against: Luciano Nardo, UK

Differed embryo transfer (DET) is bound to improve outcomes. Should we cryopreserve oocytes or embryos? TBA

Subclinical hypothyroidism is a major cause of infertility in women: George J. Kahaly, Germany

15:30-16:00 | Coffee Break

16:00-18:00 | SESSION 7A: NEW INNOVATIONS IN BIOMARKERS DEVELOPMENT AND USE

AMH, FSH and AFC: can these markers guide us in cases of ovarian cysts and endometriosis surgery? Ludwig Kiesel, Germany

Genomics, epigenomics, transcriptomics, proteomics and metabolomics: what should be the focus in looking at the human endometrium?: Jose Horcajadas, Spain

G-CSF: does it add real value to IVF success? Norbert Gleicher, USA

Mechanical irritation of the endometrium: is this the answer? Salim Daya, Canada

SESSION 7B: PCOS

IVM: finalizing the best protocol for the procedure: Seang Lin Tan, Canada

“Burning out” PCOS patients: Norbert Gleicher, USA

Optimal approach to adenosomyosis and endometriosis treatment: Adenosomyosis: the optimal approach: Umit Inceboz, Turkey

Is the vaginal mucosa the best route to administer steroids to treat endometriosis? Hugo Maia Jr, Brazil

SATURDAY, MAY 16, 2015

08:30-10:30 | SESSION 8: EMBRYO EVALUATION AND LUTEAL SUPPORT

The 3D embryo evaluation: a dream turned into a reality: Samir Hammaha, France

Innovative luteal phase support: new options for enduring challenges

Luteal phase support (LPS) is necessary in all forms of controlled ovarian stimulation (COS) cycles. What drugs are needed and how can they be delivered using better physiological methods?: Dominique deZiegler, France

Luteal phase support: dose ranging issues: Christian de Geyter, Switzerland

Luteal coasting post GnRH agonist trigger: Shachar Kol, Israel

10:30-11:00 | Coffee Break

11:00-13:00 | SESSION 9: INNOVATION IN TREATMENT PROTOCOLS

Debate: Natural cycle and minimal stimulation: is it a realistic approach or should it be abandoned? For: Thomas Strowitzki, Germany Against: David Barad, USA

Double stimulation: should this be a routine procedure in poor responders? Is it a possible solution? Dominique deZiegler, France

Metformin: a treatment for all patients undergoing infertility treatment? David Barad, USA